Rejecting the advice of the US Solicitor General, the US Supreme Court agreed to hear Amgen, Inc.’s challenge of an appeals court ruling invalidating its Repatha (evolocumab) patents for lack of enablement. The court’s decision could have broad ramifications for the biotechnology and pharmaceutical industries, which rely on patent genus claims like those at issue in this dispute.
The court granted Amgen’s petition for certiorari in orders issued on 4 November following its conference that day